Cargando…

Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis

BACKGROUND: Most immune-related adverse event (irAE) patterns and treatment guidelines are based on western clinical data. We evaluated the incidence and patterns of irAEs in patients treated with immune-checkpoint inhibitors (ICI) in Thailand. METHODS: All solid tumor patients treated with ICIs wer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ngamphaiboon, Nuttapong, Ithimakin, Suthinee, Siripoon, Teerada, Sintawichai, Nattaya, Sriuranpong, Virote
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8620529/ https://www.ncbi.nlm.nih.gov/pubmed/34823493 http://dx.doi.org/10.1186/s12885-021-09003-z

Ejemplares similares

Clinical Study of Long-Term Survival in Colorectal Cancer Patients in Thailand: A 10-Year Follow-Up
por: Thokanit, Nintita Sripaiboonkij, et al.
Publicado: (2022)

Efficacy, Safety, and Patient-Reported Outcomes of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Thailand: A Multicenter Prospective Study
por: Charonpongsuntorn, Chanchai, et al.
Publicado: (2022)

Discrepancy in p16 expression in patients with HPV-associated head and neck squamous cell carcinoma in Thailand: clinical characteristics and survival outcomes
por: Arsa, Lalida, et al.
Publicado: (2021)

Plasma extracellular vesicle microRNA‐491‐5p as diagnostic and prognostic marker for head and neck squamous cell carcinoma
por: Panvongsa, Wittaya, et al.
Publicado: (2021)

Vaccine-Related adverse events following AZD1222 (ChAdOx1-nCoV-19) Covid-19 vaccine in solid malignancy patients receiving cancer treatment, as compared to age-matched healthy controls
por: Pakvisal, Nussara, et al.
Publicado: (2022)

Durability of Immune Response to ChAdOx1-nCoV-19 Vaccine in Solid Cancer Patients Undergoing Anticancer Treatment
por: Wanchaijiraboon, Passakorn, et al.
Publicado: (2022)

Optimal cumulative dose of cisplatin for concurrent chemoradiotherapy among patients with non-metastatic nasopharyngeal carcinoma: a multicenter analysis in Thailand
por: Ngamphaiboon, Nuttapong, et al.
Publicado: (2020)

Pancreatic adverse events in patients treated with immune checkpoint inhibitors
por: Hana, Caroline, et al.
Publicado: (2023)

Effects of Complementary and Alternative Medicine on Chemotherapy Delivery in Thai Patients
por: Rabiltossaporn, Chawanya, et al.
Publicado: (2021)

Ocular adverse events with immune checkpoint inhibitors
por: Fang, Tony, et al.
Publicado: (2019)

Mucocutaneous adverse events to immune checkpoint inhibitors
por: Muhaj, Fiorinda, et al.
Publicado: (2023)

Unexpected Adverse Events of Immune Checkpoint Inhibitors
por: Shalata, Walid, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events
por: Herrmann, Sandra M., et al.
Publicado: (2020)

Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)
por: Daban, A, et al.
Publicado: (2023)

Rheumatic immune‐related adverse events induced by immune checkpoint inhibitors
por: Zhong, Hui, et al.
Publicado: (2020)

Ophthalmic immune-related adverse events associated with immune checkpoint inhibitors
por: Gan, Linyang, et al.
Publicado: (2023)

Immune-related adverse events of immune checkpoint inhibitors: a review
por: Yin, Qinan, et al.
Publicado: (2023)

Cardiac Adverse Events Related to Immune Checkpoint Inhibitors
por: Gujral, Dorothy M., et al.
Publicado: (2020)

Effect of Primary Tumor Location on Second- or Later-Line Treatment With Anti-Epidermal Growth Factor Receptor Antibodies in Patients With Metastatic Colorectal Cancer: A Retrospective Multi-Center Study
por: Archwamety, Anita, et al.
Publicado: (2022)

Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer
por: Wangchinda, Pattaraporn, et al.
Publicado: (2016)

Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
por: Das, Satya, et al.
Publicado: (2019)

Equibalancing immune‐related adverse events and anticancer activity of immune checkpoint inhibitors
por: Seeruttun, Sharvesh Raj
Publicado: (2019)

Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors
por: Choi, Juwhan, et al.
Publicado: (2020)

The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors
por: Jia, Xiao-Hui, et al.
Publicado: (2020)

Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors
por: Dolladille, Charles, et al.
Publicado: (2020)

Pembrolizumab- and ipilimumab-induced diabetic ketoacidosis and isolated adrenocorticotropic hormone deficiency: a case report
por: Porntharukchareon, Thachanun, et al.
Publicado: (2020)

Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors
por: Wang, Zheng-Hang, et al.
Publicado: (2018)

Management of immune checkpoint inhibitor‐related dermatologic adverse events
por: Si, Xiaoyan, et al.
Publicado: (2019)

Management of immune checkpoint inhibitor‐related rheumatic adverse events
por: Zhou, Jiaxin, et al.
Publicado: (2019)

Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy
por: Rajha, Eva, et al.
Publicado: (2019)

Immune checkpoint inhibitors, endocrine adverse events, and outcomes of melanoma
por: Karhapää, Hanna, et al.
Publicado: (2022)

Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events
por: Poto, Remo, et al.
Publicado: (2022)

Management of Hematologic Adverse Events Associated With Immune Checkpoint Inhibitors
por: Rogers, Barbara Barnes, et al.
Publicado: (2021)

Thyroid-related adverse events induced by immune checkpoint inhibitors
por: Chera, Alexandra, et al.
Publicado: (2022)

Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events
por: Les, Iñigo, et al.
Publicado: (2023)

Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac
por: Wanchaijiraboon, Passakorn, et al.
Publicado: (2023)

Analysis of immune‐related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database
por: Hasegawa, Shiori, et al.
Publicado: (2020)

Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade
por: Hu, Weilei, et al.
Publicado: (2020)

Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review
por: Stelmachowska-Banaś, Maria, et al.
Publicado: (2020)

Association of immune-related adverse events with immune checkpoint inhibitor efficacy: real or imaginary?
por: Haratani, Koji, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_puddrve2c1tm8ihgokhrja0b12